Aspergillosis

News Aspergillosis

• Basilea and Astellas update isavuconazole phase III trial in consultation with FDA

  Basilea Pharmaceutica Ltd. announced that in consultation with the U.S. Food and Drug Administration (FDA) Basilea and its partner Astellas Pharma Inc. have agreed to use 'all-cause mortality' as the primary endpoint of the phase III clinical study investigating isavuconazole for the treatment of in more

• Basilea provides update on phase III program for the antifungal isavuconazole

  Basilea Pharmaceutica Ltd. announced that its partner Astellas Pharma Inc.has initiated the formal process to allow continuation of patient recruitment into the phase III clinical studies of isavuconazole for the treatment of life-threatening invasive fungal infections. Certain study protocol amendm more

• Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox

  HalcyGen Pharmaceuticals Limited announced that preliminary results from its UK-based pharmacokinetic study (PK) comparing a half-dose of anti-fungal drug SUBA-Itraconazole with Sporanox®, has shown clinical bioequivalence within EU guidelines. Following a pre-registration meeting with the regulator more